CA2819679A1 - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents

Compositions and methods for treating amyloid plaque associated symptoms Download PDF

Info

Publication number
CA2819679A1
CA2819679A1 CA2819679A CA2819679A CA2819679A1 CA 2819679 A1 CA2819679 A1 CA 2819679A1 CA 2819679 A CA2819679 A CA 2819679A CA 2819679 A CA2819679 A CA 2819679A CA 2819679 A1 CA2819679 A1 CA 2819679A1
Authority
CA
Canada
Prior art keywords
seq
antibody
amino acid
apoe
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2819679A
Other languages
English (en)
French (fr)
Inventor
David Holtzman
Jungsu Kim
Hong Jiang
Adam Eltorai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of CA2819679A1 publication Critical patent/CA2819679A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2819679A 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms Abandoned CA2819679A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
CA2819679A1 true CA2819679A1 (en) 2012-06-07

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2819679A Abandoned CA2819679A1 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Country Status (14)

Country Link
US (2) US20140037638A1 (2)
EP (1) EP2646053A4 (2)
JP (1) JP2014502276A (2)
KR (1) KR20140017513A (2)
CN (1) CN103338786A (2)
AU (1) AU2011336360A1 (2)
BR (1) BR112013013723A2 (2)
CA (1) CA2819679A1 (2)
MX (1) MX2013006116A (2)
NZ (1) NZ611614A (2)
RU (1) RU2013130002A (2)
SG (1) SG190952A1 (2)
WO (1) WO2012075422A2 (2)
ZA (1) ZA201303996B (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2016054247A1 (en) 2014-09-30 2016-04-07 Washington University Tau kinetic measurements
EP3452074A4 (en) * 2016-05-03 2019-12-11 University of South Florida COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
EP3655026A4 (en) 2017-07-17 2021-07-28 Janssen Biotech, Inc. ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
AU2020282792B2 (en) * 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
US20240400659A1 (en) * 2021-10-19 2024-12-05 Bioatla, Inc. Conditionally active proteins for neurodegenerative diseases
JP2025540077A (ja) * 2022-11-30 2025-12-11 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ナチュラルキラー細胞エンゲージャー
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
RU2006122946A (ru) * 2003-11-28 2008-01-10 Астразенека Аб (Se) Антитела
EP1736162A1 (en) * 2004-03-30 2006-12-27 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
US20070248599A1 (en) * 2006-02-21 2007-10-25 Jordan Tang Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2542581A4 (en) * 2010-03-01 2014-01-22 David Gladstone Inst APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
WO2012075422A3 (en) 2012-10-04
MX2013006116A (es) 2013-10-17
NZ611614A (en) 2015-07-31
EP2646053A2 (en) 2013-10-09
AU2011336360A1 (en) 2013-07-04
ZA201303996B (en) 2015-10-28
US20140037638A1 (en) 2014-02-06
KR20140017513A (ko) 2014-02-11
WO2012075422A2 (en) 2012-06-07
JP2014502276A (ja) 2014-01-30
BR112013013723A2 (pt) 2019-09-24
EP2646053A4 (en) 2014-05-28
US20160355581A1 (en) 2016-12-08
RU2013130002A (ru) 2015-01-10
CN103338786A (zh) 2013-10-02
SG190952A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US20160355581A1 (en) Compositions and methods for treating amyloid plaque associated symptoms
TWI705975B (zh) 抗－N3pGlu類澱粉β肽抗體及其用途
AU2006319358B2 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
CN1426423B (zh) 螯合淀粉样蛋白β肽的人源化抗体
US20230416393A1 (en) Cd6 antibody for treatment of t-cell mediated diseases or disorders
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
US8741298B2 (en) APOE immunotherapy
US7122374B1 (en) Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
US20100322932A1 (en) Methods for amyloid removal using anti-amyloid antibodies
CN112166121B (zh) 神经生长因子的单克隆抗体及其编码基因和应用
CA3077304C (en) Anti-pacap antibody
CN105431203A (zh) 治疗性融合蛋白
JP2019514994A (ja) 脊髄性筋萎縮症を治療するための組成物及び方法
CN115175932B (zh) 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CA3030872A1 (en) Compositions and methods for treating frontotemporal dementia
AU2023200728A1 (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
JP2024506409A (ja) 抗体
WO2025119350A1 (zh) 靶向Tau的特异性结合蛋白及其应用
US20230090965A1 (en) Prophylactic or therapeutic agent for dementia
HK40005250A (en) Compositions and methods for treating spinal muscular atrophy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20171204